Xponance’s Alexion Pharmaceuticals ALXN Stock Holding History

Xponance’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,207	Closed	-$2.24M	–	1260
2021 Q2	$2.24M	Sell	12,207 -582	-5%	-$99.9K	0.04%	343
2021 Q1	$1.96M	Sell	12,789 -37	-0.3%	-$5.72K	0.04%	320
2020 Q4	$2M	Buy	12,826 +593	+5%	+$76.2K	0.04%	317
2020 Q3	$1.4M	Sell	12,233 -107	-0.9%	-$11.5K	0.03%	350
2020 Q2	$1.39M	Buy	+12,340	New	+$1.31M	0.04%	317

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Xponance's ALXN Position: Q3 2021 in Review

Xponance sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 12,207 shares — an estimated $2.24M sold.

Xponance first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $2.24M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Xponance reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Xponance sold 12,207 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.24M.
Xponance first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Xponance's Alexion Pharmaceuticals position peaked at $2.24M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Xponance's 13F filing for Q3 2021, filed 5 Nov 2021.